<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Magnussen | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/plaindoor91/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/plaindoor91/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Magnussen.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">062b33cd41dd222b5bbce0c36491c1cd</guid>
				<title>Magnussen posted an update: Both non-sustained ventricular tachycardia of ≥4 beats and ≥ [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/42982/</link>
				<pubDate>Sun, 09 Feb 2025 12:17:10 -0800</pubDate>

									<content:encoded><![CDATA[<p>Both non-sustained ventricular tachycardia of ≥4 beats and ≥20 PVCs/24 h independently predicted mortality in univariate and multivariate survival analyses, adjusted for all other univariate predictors of mortality as well as relevant clinical factors, including cancer stage and type, performance status (ECOG), prior potentially cardiotoxic ant&hellip;<span class="activity-read-more" id="activity-read-more-42982"><a href="http://www.nationalboardinstitute.com/activity/p/42982/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ba0ed225408643d9a5d22306f5a417e1</guid>
				<title>Magnussen posted an update: 3%-98.3%; NPV, 75.0%-98.7%; ±15-day agreement, 95.6%-97.6%; [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41978/</link>
				<pubDate>Sat, 08 Feb 2025 11:45:37 -0800</pubDate>

									<content:encoded><![CDATA[<p>3%-98.3%; NPV, 75.0%-98.7%; ±15-day agreement, 95.6%-97.6%; and median rwOS estimates ranging from 2.8% to 12.7% greater. Sensitivity analysis results (n=17 540) were consistent with the main analysis.</p>
<p> Across all cancer types analyzed, this composite mortality variable showed high sensitivity, specificity, PPV, NPV, and ±15-day agr&hellip;<span class="activity-read-more" id="activity-read-more-41978"><a href="http://www.nationalboardinstitute.com/activity/p/41978/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f3560dfe85b1eefa6ecb307e959ac4a1</guid>
				<title>Magnussen posted an update: The number of studies on autonomous vehicles has increased [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/40463/</link>
				<pubDate>Thu, 06 Feb 2025 16:34:20 -0800</pubDate>

									<content:encoded><![CDATA[<p>The number of studies on autonomous vehicles has increased over recent years. Many of these studies have indicated the importance of an external Human-Machine Interface of communication (eHMI) on autonomous vehicles to indicate their intentions to other road users. <a href="https://www.selleckchem.com/products/alc-0159.html" rel="nofollow ugc">ALC-0159 molecular weight</a> Using an experimental design, we compared three eHMIs&hellip;<span class="activity-read-more" id="activity-read-more-40463"><a href="http://www.nationalboardinstitute.com/activity/p/40463/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f90bc39ae68fa2a744a74258e77bff69</guid>
				<title>Magnussen posted an update: Not least for this reason, the treadmill paradox, or Red [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38645/</link>
				<pubDate>Tue, 04 Feb 2025 12:12:59 -0800</pubDate>

									<content:encoded><![CDATA[<p>Not least for this reason, the treadmill paradox, or Red Queen effect, easily discernable in market economies as a driver for change, whether progressive or destructive or both, can fruitfully be applied as an analytical lens through which to view sport. The question nevertheless remains to be answered as to whether the improved achievements of&hellip;<span class="activity-read-more" id="activity-read-more-38645"><a href="http://www.nationalboardinstitute.com/activity/p/38645/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">8ed96c8e04a2dd69aa8afe7dd5cd8af6</guid>
				<title>Magnussen posted an update: Renal denervation (RDN) is a new treatment for hypertension [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36795/</link>
				<pubDate>Sun, 02 Feb 2025 11:59:40 -0800</pubDate>

									<content:encoded><![CDATA[<p>Renal denervation (RDN) is a new treatment for hypertension in patients with chronic kidney disease (CKD), but its efficacy is still debated. This meta-analysis aimed to evaluate the efficacy and safety of RDN for hypertension in patients with CKD.</p>
<p> PubMed, Web of Science, EMBASE, and Ovid databases were searched for relevant studies&hellip;<span class="activity-read-more" id="activity-read-more-36795"><a href="http://www.nationalboardinstitute.com/activity/p/36795/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e438274cb52ecd661cb1644618bbf8b6</guid>
				<title>Magnussen posted an update: Medline, Embase, Web of Science, CINAHL and Cochrane [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/35021/</link>
				<pubDate>Fri, 31 Jan 2025 12:37:00 -0800</pubDate>

									<content:encoded><![CDATA[<p>Medline, Embase, Web of Science, CINAHL and Cochrane Database of systematic reviews were searched for English-language reviews published between 2015 and 2020.</p>
<p> The search yielded 2266 articles, of which 12 systematic reviews met criteria. Sixteen reviews were included in total, after four reviews were found via handsearching. Other than&hellip;<span class="activity-read-more" id="activity-read-more-35021"><a href="http://www.nationalboardinstitute.com/activity/p/35021/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">56496da7887ea8c9b72f090a2e7bc188</guid>
				<title>Magnussen posted an update: 2 - 12.4%. The method was used to study in vivo brain uptake [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/30857/</link>
				<pubDate>Tue, 28 Jan 2025 15:50:57 -0800</pubDate>

									<content:encoded><![CDATA[<p>2 &#8211; 12.4%. The method was used to study in vivo brain uptake and pharmacokinetics of galantamine from brain homogenate and plasma samples following the administration of nasal galantamine-bound chitosan nanoparticles compared to oral and nasal galantamine solutions, in scopolamine-induced Alzheimer&#8217;s disease rat model.Glaucoma is a multifactorial&hellip;<span class="activity-read-more" id="activity-read-more-30857"><a href="http://www.nationalboardinstitute.com/activity/p/30857/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">9486436f013277802b86273655ffdf1c</guid>
				<title>Magnussen became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/30812/</link>
				<pubDate>Tue, 28 Jan 2025 15:45:56 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>